 "Ipca Laboratories slips on USFDA import alert report")
Shares of Ipca Laboratories slipped 5% to Rs 663 on BSE on media reports that the company got US Food and Drug Administration (FDA) import alert for Ratlam plant.
The USFDA has banned imports from Indian generic drugmaker Ipca Laboratories Ltd's plant at Ratlam in Madhya Pradesh due to violations of standard production practices, the Reuters report suggest.
The FDA announced the ban, called import alert, in a notice on its website late on Thursday. It did not elaborate, added report.
The stock opened at Rs 659 and touched a low of Rs 640 on BSE. The counter has seen huge trading volumes with a combined 1.18 million shares changed hands till 1045 hours against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
The USFDA has banned imports from Indian generic drugmaker Ipca Laboratories Ltd's plant at Ratlam in Madhya Pradesh due to violations of standard production practices, the Reuters report suggest.
The FDA announced the ban, called import alert, in a notice on its website late on Thursday. It did not elaborate, added report.
The stock opened at Rs 659 and touched a low of Rs 640 on BSE. The counter has seen huge trading volumes with a combined 1.18 million shares changed hands till 1045 hours against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%